Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical management of relapsed and refractory acute myeloid leukemia
ChiCTR1900023976Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jan 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of filgrastim, cladribine, cytarabine, homoharringtonine, azacitidine and 1 more in acute myeloid leukemia (AML) (2 arms), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: Influencing factors of drug resistance. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
filgrastimcladribinecytarabinehomoharringtonineazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900023976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023976.